Global drug development consultancy Boyds has added to its team with the appointment of experienced regulatory affairs professional Katherine Bowen in response to a rise in demand for its specialist regulatory services.

With more than 14 years’ experience in regulatory affairs across both mid to large pharma and consultancies, Bowen joins Boyds as senior director of regulatory affairs.

Bowen joins Boyds from regulatory consultancy DLRC where she was head of regulatory teams and principal consultant leading a team of regulatory consultants as well as providing strategic and operational regulatory advice to clients. Prior to this, she worked for companies including Eli Lilly and Amgen across a range of therapeutic areas from early phase to regulatory approval.

Bowen has a PhD in neuroscience from the University of Cambridge where she studied mechanisms of axon degeneration in inflammatory, demyelinating disorders.

At Boyds, Bowen will lead client projects and provide strategic regulatory advice to facilitate regulatory input, incentives, and early market access.
 
“We continue to see an increased demand from biotechs and academic groups looking for our regulatory expertise and support, particularly in advanced therapy medicinal products (ATMPs), and cell and gene therapies,” said Julie Warner, vice president of regulatory affairs, Boyds. “Katherine’s experience and proven track record of providing strategic regulatory advice across a range of therapeutic areas will be invaluable as we continue to build on this growth and add real value to clients looking to bring their medicines to the market.”

Boyds was established in 2005 by Professor Alan Boyd and provides specialist consultancy services to a global client base, supporting the development of new, cutting-edge medicines for patient benefit.